Heron Therapeutics Inc

HRTXNASDAQ · USD
0.26USD0.00 (-0.80%)
442

Heron Therapeutics Inc (HRTX) Covered Calls

Heron Therapeutics Inc trades in the Biotechnology industry with an IV Rank of 86.51%, high versus the past year. HRTX's highest covered call setup is the $0.50 strike expiring Jun 17, 2027, sorted by theoretical annualized return. It's 85.19% out of the money with 211 days to expiration, a 103.70% return until expiration, and a 179.39% theoretical annualized return. Across the setups shown, annualized returns run from 179.39% to 179.39% at strikes between $0.50 and $0.50, with 211 days to expiration, as of Nov 18, 2026.

Read more

Running HRTX covered calls helps you generate income from Heron Therapeutics Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best HRTX covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If HRTX stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling HRTX covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given HRTX covered call is worth writing.

Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy.

2027-06-172110.5085.190.051.0528.00103.70179.39-18.52+1.0011.00

As of Nov 18, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV Rank86.51% High
  • Market cap (M$)50
  • 52 weeks high-83.54%
  • 52 weeks low0.00%
  • Analyst recommendationHold
    3.00
  • Target price$0.34
    29.77% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-11-09
  • P/E—
  • Future P/E—
  • EPS (ttm)-0.11
  • EPS growth next 5 years16.15%

As of Nov 19, 2026